IFNG and influenza: As reviewed by Van Reeth et Ma in 2013, an intranasal route or an endotracheal route using a lower swIAV dose lead to slower and lower viral load peaks in lungs, milder lung inflammation (lower levels of IFNa, IFNg and pro-inflammatory cytokines in BALF) and less influenza-specific symptoms [40].